Statins and hemoperfusion improve 28-day survival in septic shock patients

• Authors: Tsukasa Nakamura , Eiichi Sato , Nobuharu Fujiwara , Yasuhiro Kawagoe , Sayaka Maeda , Hiroyoshi Inoue , Sho-ichi Yamagishi
• Languages of publication: EN

Abstracts

EN

Uncontrolled inflammation and endotoxin play a central role in septic shock. Statins may possess anti-inflammatory properties, and removal of endotoxin by hemoperfusion with polymyxin B-immobilized fiber (PMX-F) could have favorable effects on sepsis. We examined retrospectively whether pre-existing statin and hemoperfusion with PMX-F at the time of admission were separately and independently associated with decreased overall 28-day mortality in septic shock patients. Consecutive 173 patients with septic shock (71.2±10.7 years old, 115 male and 58 female) were included in the present study. All patients underwent a complete history and physical examination, determination of blood chemistries. Multiple stepwise regression analysis revealed that albumin, creatinine (inversely), statin use, hemoperfusion with PMX-F and HDL-cholesterol were independently correlated to 28-day survival in septic shock patients (R2=0.464). Our present study suggests that pre-existing statin use and hemoperfusion with PMX-F may separately and independently contribute to blunt the process of septic shock.

Keywords

EN

Statins; PMX-F; Septic shock; Inflammation

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2012
• Volume: 7
• Issue: 4
• Pages: 475-480

Dates

published

1 - 8 - 2012

online

24 - 5 - 2012

Contributors

author

Tsukasa Nakamura

• Division of Nephrology, Department of Internal Medicine, Shinmatsudo Central General Hospital, Matsudo, 270-0034, Japan

author

Eiichi Sato

• Division of Nephrology, Department of Internal Medicine, Shinmatsudo Central General Hospital, Matsudo, 270-0034, Japan

author

Nobuharu Fujiwara

• Division of Nephrology, Department of Internal Medicine, Shinmatsudo Central General Hospital, Matsudo, 270-0034, Japan

author

Yasuhiro Kawagoe

• Division of Nephrology, Department of Internal Medicine, Shinmatsudo Central General Hospital, Matsudo, 270-0034, Japan

author

Sayaka Maeda

• Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume, 830-0011, Japan

author

Hiroyoshi Inoue

• Department of Chemistry, Keio University School of Medicine, Yokohama, 223-8521, Japan

author

Sho-ichi Yamagishi

• Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume, 830-0011, Japan

References

• [1] Winters BD, Eberlein M, Leung J, et al: Long-term mortality and quality of life in sepsis: a systematic review. Crit Care Med 2010; 38: 1276–1283
• [2] Nakamura T, Yamagishi SI: PEDF and septic shock. Curr Mol Med 2010; 10: 312–316 http://dx.doi.org/10.2174/156652410791065246[Crossref][WoS]
• [3] Cohen J: Non-antibiotic strategies for sepsis. Clin Microbiol Infect 2009; 15: 302–307 http://dx.doi.org/10.1111/j.1469-0691.2009.02753.x[Crossref][WoS]
• [4] Zhou Q, Liao JK: Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr Pharm Des 2009; 15: 467–478 http://dx.doi.org/10.2174/138161209787315684[WoS][Crossref]
• [5] Karalis DG: The role of lipid-lowering therapy in preventing coronary heart disease in patients with type 2 diabetes. Clin Cardiol 2008; 31: 241–248. http://dx.doi.org/10.1002/clc.20226[Crossref]
• [6] Singh V, Deedwania P: Reducing morbidity and mortality in high risk patients with statins. Vasc Health Risk Manag 2009; 5: 495–507 [PubMed]
• [7] Mensah K, Mocanu MM, Yellon DM: Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten? J Am Coll Cardiol 2005; 45: 1287–1291 http://dx.doi.org/10.1016/j.jacc.2005.01.021[Crossref]
• [8] Yamagishi S, Matsui T, Nakamura K: Atorvastatin and diabetic vascular complications. Curr Pharm Des 2006; 12: 1549–1554 http://dx.doi.org/10.2174/138161206776389796[Crossref]
• [9] Schönbeck U, Libby P: Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 2004; 109(21 Suppl 1): II 18–26
• [10] Shovman O, Levy Y, Gilburd B, Shoenfeld Y: Antiinflammatory and immunomodulatory properties of statins. Immunol Res 2002; 25: 271–285 http://dx.doi.org/10.1385/IR:25:3:271[Crossref]
• [11] Yamagishi S: Possible involvement of advanced glycation end products in carry-over benefits of atorvastatin in ASCOT-BPLA. Eur Heart J 2008; 29: 1922 http://dx.doi.org/10.1093/eurheartj/ehn244[WoS][Crossref]
• [12] Chalmers JD, Short PM, Mandal P, Akram AR, Hill AT: Statins in community acquired pneumonia: Evidence from experimental and clinical studies. Respir Med 2010; 104: 1081–1091 http://dx.doi.org/10.1016/j.rmed.2010.04.005[Crossref]
• [13] Prinz V, Endres M: The acute (cerebro)vascular effects of statins. Anesth Analg 2009; 109: 572–584 http://dx.doi.org/10.1213/ane.0b013e3181a85d0e[Crossref][WoS]
• [14] Goodin J, Manrique C, Dulohery M, Sampson J, Saettele M, Dabbagh O: Effect of statins on the clinical outcomes of patients with sepsis. Anaesth Intensive Care 2011; 39: 1051–1055 [PubMed]
• [15] Shoji H, Tani T, Hanasawa K, et al: Extracorporeal endotoxin removal by polymyxin B immobilized fiber cartride: designing and antiendotoxin efficacy in the clinical application. Ther Apher 1998; 2: 3–12 http://dx.doi.org/10.1111/j.1744-9987.1998.tb00066.x[Crossref]
• [16] Tani T, Hanasawa K, Kodama M, et al: Correlation between plasma endotoxin, plasma cytokines, and plasminogen activator inhibitor-1 activities in septic patients. World J Surg 2001; 25: 660–668 http://dx.doi.org/10.1007/s002680020028
• [17] Vincent JL, Laterre PF, Cohen J, et al: A pilotcontrolled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 2005; 23: 400–405 http://dx.doi.org/10.1097/01.shk.0000159930.87737.8a[Crossref]
• [18] American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864–874 http://dx.doi.org/10.1097/00003246-199206000-00025[Crossref]
• [19] Nakamura T, Sugaya T, Koide H: Urinary liver-type fatty acid-binding protein in septic shock. Effect of polymyxin B-immobilized fiber hemoperfusion. Shock 2009; 31: 454–459 [WoS][Crossref][PubMed]
• [20] Vincent JL, Moreno R, Takala J, et al: The SOFA score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-related Problems of the European Society of Intensive Care Medicine. Intens Care Med 1986; 22: 707–710 http://dx.doi.org/10.1007/BF01709751[Crossref]
• [21] Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818–829 http://dx.doi.org/10.1097/00003246-198510000-00009[Crossref]
• [22] Nakamura T, Sato E, Fujiwara N, et al: Coadministration of ezetimibe enhances proteinurialowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterolindependent manner. Pharmacol Res 2010; 61: 58–61 http://dx.doi.org/10.1016/j.phrs.2009.07.011[Crossref]
• [23] Mortensen EM, Restrepo MI, Copeland LA, et al: Impact of previous statin and angiotensin II receptor blocker use on mortality in patients hospitalized with sepsis. Pharmacotherapy 2007; 27: 1619–1626 http://dx.doi.org/10.1592/phco.27.12.1619[Crossref][WoS]
• [24] Almog Y, Novack V, Eisinger M, et al: The effect of statin therapy on infection-related mortality in patients with atherosclerotic diseases. Crit Care Med 2007; 35: 372–378 http://dx.doi.org/10.1097/01.CCM.0000253397.42079.D5[Crossref]
• [25] Yang KC, Chien JY, Tseng WK, et al: Statins do not improve short-term survival in an oriental population with sepsis. Am J Emerg Med 2007; 25: 494–501 http://dx.doi.org/10.1016/j.ajem.2006.09.011[WoS][Crossref]
• [26] Martin CP, Talbert RL, Burgess DS, Peters JI: Effectiveness of statins in reducing the rate of severe sepsis: a retrospective evaluation. Pharmacotherapy 2007; 27: 20–26 http://dx.doi.org/10.1592/phco.27.1.20[Crossref][WoS]
• [27] Fernandez R, De Pedro VJ, Artigas A: Statin therapy prior to ICU admission: protection against infection or a severity marker? Intensive Care Med 2006; 32: 160–164 http://dx.doi.org/10.1007/s00134-005-2743-9[Crossref]
• [28] Cruz DN, de Cal M, Piccinni P, Ronco C: Polymyxin-B hemoperfusion and endotoxin removal: lessons from a review of the literature. Contrib Nephrol 2010; 167: 77–82 http://dx.doi.org/10.1159/000315921[Crossref]
• [29] Cruz DN, Perazella MA, Bellomo R, de Cal M, Polanco N, Corradi V, et al. Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care 2007; 11: R47 http://dx.doi.org/10.1186/cc5780[WoS][Crossref]
• [30] Chen HP, Chen TL, Lai CH, et al: Predictors of mortality in Acinetobacter baumannii bacteremia. J Microbiol Immunol Infect 2005; 38: 127–136 [WoS]
• [31] Leibovici L, Samra Z, Konigsberger H, et al: Longterm survival following bacteremia or fungemia. JAMA 1995; 274: 807–812 http://dx.doi.org/10.1001/jama.1995.03530100047033[Crossref]
• [32] Norata GD, Catapano AL: Molecular mechanisms responsible for the antiinflammatory and protective effect of HDL on the endothelium. Vasc Health Risk Manag 2005; 1: 119–129 http://dx.doi.org/10.2147/vhrm.1.2.119.64083[Crossref]
• [33] Cho KH: Biomedicinal implications of high-density lipoprotein: its composition, structure, functions, and clinical applications. BMB Rep 2009; 42: 393–400 http://dx.doi.org/10.5483/BMBRep.2009.42.7.393[Crossref]

Identifiers

DOI

10.2478/s11536-011-0169-z